<SEC-DOCUMENT>0001493215-25-000037.txt : 20251114
<SEC-HEADER>0001493215-25-000037.hdr.sgml : 20251114
<ACCEPTANCE-DATETIME>20251114082427
ACCESSION NUMBER:		0001493215-25-000037
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20251114
DATE AS OF CHANGE:		20251114

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aquestive Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001398733
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				208623253
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-90885
		FILM NUMBER:		251481424

	BUSINESS ADDRESS:	
		STREET 1:		30 TECHNOLOGY DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059
		BUSINESS PHONE:		908-941-1900

	MAIL ADDRESS:	
		STREET 1:		30 TECHNOLOGY DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MonoSol Rx, Inc.
		DATE OF NAME CHANGE:	20070507

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RTW INVESTMENTS, LP
		CENTRAL INDEX KEY:			0001493215
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		40 10TH AVENUE
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10014
		BUSINESS PHONE:		646-597-6980

	MAIL ADDRESS:	
		STREET 1:		40 10TH AVENUE
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10014

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RTW INVESTMENTS, LLC
		DATE OF NAME CHANGE:	20100602
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
	    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001493215</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>





    </filerInfo>
  </headerData>

  <formData>
    <coverPageHeader>
	      <securitiesClassTitle>Common Stock, $0.001 par value</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>09/30/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001398733</issuerCik>        <issuerName>Aquestive Therapeutics, Inc.</issuerName>        <issuerCusip>03843E104</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>30 Technology Drive</com:street1>
                    <com:city>Warren</com:city>
          <com:stateOrCountry>NJ</com:stateOrCountry>
          <com:zipCode>07059</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>

	        <designateRulesPursuantThisScheduleFiled>
	   		        <designateRulePursuantThisScheduleFiled>Rule 13d-1(b)</designateRulePursuantThisScheduleFiled>
				      </designateRulesPursuantThisScheduleFiled>

    </coverPageHeader>

	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>RTW Investments, LP</reportingPersonName>



		 <citizenshipOrOrganization>DE</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>6250000.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>6250000.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>6250000.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>5.2</classPercent>




	  	  	  	  <typeOfReportingPerson>IA</typeOfReportingPerson>

	        <typeOfReportingPerson>PN</typeOfReportingPerson>









    </coverPageHeaderReportingPersonDetails>
	    <coverPageHeaderReportingPersonDetails>




    <reportingPersonName>Roderick Wong</reportingPersonName>



		 <citizenshipOrOrganization>X1</citizenshipOrOrganization>

      <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>0.00</soleVotingPower>
                          <sharedVotingPower>6250000.00</sharedVotingPower>
                          <soleDispositivePower>0.00</soleDispositivePower>
                         <sharedDispositivePower>6250000.00</sharedDispositivePower>
             </reportingPersonBeneficiallyOwnedNumberOfShares>

              <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>6250000.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>


     	    <classPercent>5.2</classPercent>







	        <typeOfReportingPerson>HC</typeOfReportingPerson>



	        <typeOfReportingPerson>IN</typeOfReportingPerson>




    </coverPageHeaderReportingPersonDetails>

    <items>
      <item1>
        <issuerName>Aquestive Therapeutics, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>30 Technology Drive, Warren, NJ, 07059.</issuerPrincipalExecutiveOfficeAddress>
      </item1>

      <item2>
        <filingPersonName>This statement is filed by:

(i) RTW Investments, LP ("RTW Investments"), a Delaware limited partnership and the investment adviser to certain funds (the "RTW Funds"), with respect to shares of Common Stock, par value $0.001 per share (the "Shares") of Aquestive Therapeutics, Inc.  (the "Company") directly held by the RTW Funds; and

(ii) Roderick Wong, M.D. ("Dr. Wong"), the Managing Partner and Chief Investment Officer of RTW Investments, with respect to the Shares directly held by the RTW Funds.

The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."

The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, as amended, the beneficial owner of the Shares reported herein.</filingPersonName>        <principalBusinessOfficeOrResidenceAddress>The address of the business office of each of the Reporting Persons is 40 10th Avenue, Floor 7, New York, New York 10014.</principalBusinessOfficeOrResidenceAddress>        <citizenship>RTW Investments is a Delaware limited partnership. Dr. Wong is a citizen of the United States.</citizenship>      </item2>

        <item3>
				<notApplicableFlag>N</notApplicableFlag>





		<typeOfPersonFiling>IA</typeOfPersonFiling>

		<typeOfPersonFiling>HC</typeOfPersonFiling>







      </item3>



    <item4>
    <amountBeneficiallyOwned>The information required by Item 4(a) is set forth in Rows 5 - 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentages set forth in Row 11 of the cover pages are calculated based upon 99,723,635 Shares outstanding as of August 7, 2025 as reported in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 11, 2025, plus 21,250,000 Shares issued pursuant to the Issuer's public offering that closed on August 15, 2025, as disclosed in the prospectus supplement dated August 14, 2025 and filed with the SEC on August 14, 2025.
</amountBeneficiallyOwned>    <classPercent>RTW Investments: 5.2%
Dr. Wong: 5.2%</classPercent>
      <numberOfSharesPersonHas>
        <solePowerOrDirectToVote>RTW Investments: 0
Dr. Wong: 0</solePowerOrDirectToVote>
        <sharedPowerOrDirectToVote>RTW Investments: 6,250,000 Shares
Dr. Wong: 6,250,000 Shares</sharedPowerOrDirectToVote>
        <solePowerOrDirectToDispose>RTW Investments: 0
Dr. Wong: 0</solePowerOrDirectToDispose>
        <sharedPowerOrDirectToDispose>RTW Investments: 6,250,000 Shares
Dr. Wong: 6,250,000 Shares</sharedPowerOrDirectToDispose>
      </numberOfSharesPersonHas>
    </item4>


        <item5>
	          <notApplicableFlag>Y</notApplicableFlag>


    </item5>


        <item6>
	              <notApplicableFlag>N</notApplicableFlag>
        <ownershipMoreThan5PercentOnBehalfOfAnotherPerson>See Item 2. The RTW Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein. </ownershipMoreThan5PercentOnBehalfOfAnotherPerson>
		     </item6>


        <item7>
	  	  <notApplicableFlag>Y</notApplicableFlag>


    </item7>


          <item8>
                <notApplicableFlag>Y</notApplicableFlag>

              </item8>


            <item9>
                <notApplicableFlag>Y</notApplicableFlag>
                      </item9>


      <item10>
                <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>

      </item10>
    </items>

		<exhibitInfo>Exhibit 99.1  Joint Filing Agreement</exhibitInfo>

	    <signatureInformation>
      <reportingPersonName>RTW Investments, LP</reportingPersonName>

      <signatureDetails>
        <signature>/s/ Roderick Wong, M.D.</signature>
        <title>Roderick Wong, M.D., Managing Partner</title>
        <date>11/14/2025</date>
      </signatureDetails>

    </signatureInformation>
	     <signatureInformation>
      <reportingPersonName>Roderick Wong</reportingPersonName>

      <signatureDetails>
        <signature>s/ Roderick Wong, M.D.</signature>
        <title>Roderick Wong, M.D.</title>
        <date>11/14/2025</date>
      </signatureDetails>

    </signatureInformation>



  </formData>


    </edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex-99-11142025_011125.htm
<DESCRIPTION>JOINT FILING AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//IETF//DTD HTML//EN">
<html><head><title>ex-99-11142025_011125.htm</title></head><body style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<p style="margin-top:0px; margin-bottom:17.6px; padding-left:36px; font-size:11pt" align="center"><b>EXHIBIT 99.1</b></p>
<p style="margin:0px; padding-left:36px; font-size:11pt" align="center"><b>JOINT FILING AGREEMENT</b></p>
<p style="margin-top:0px; margin-bottom:17.6px; padding-left:36px; font-size:11pt" align="center"><b>PURSUANT TO RULE 13(d)-1(k) </b></p>
<p style="margin:0px; font-size:11pt">The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.</p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:17.6px; font-size:11pt">Dated: &nbsp;November 14, 2025</p>
<p style="margin:0px; font-size:11pt"><b>RTW Investments, LP</b></p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; width:30px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; text-indent:-2px; font-size:11pt"><u>/s/ Roderick Wong, M.D.</u></p>
<p style="margin:0px; text-indent:30px; font-size:11pt; clear:left">Name: &nbsp;Roderick Wong, M.D.</p>
<p style="margin:0px; text-indent:30px; font-size:11pt">Title: &nbsp;Managing Partner</p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px; font-size:11pt"><b>Roderick Wong, M.D.</b></p>
<p style="margin:0px"><br></p>
<p style="margin:0px; font-size:11pt"><u>/s/ Roderick Wong, M.D.</u></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
</body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
